Momenta Pharmaceuticals, Inc.

Massachusetts Institute of Technology

Other

Ishan Capila

Nur Sibel Gunay

Daniela Beccati

Zachary Shriver

Jennifer Ozug

Ram Sasisekharan

Carlos J Bosques

Rahul Raman

Kevin Pojasek

Steve Wudyka

Vikas Prabhakar

Ganesh Venkataraman

Leona E Ling

Sucharita Roy

Cuihua Liu

Thomas Prod'homme

Victor Farutin

Jonathan C Lansing

Mallikarjun Sundaram

Corinne Bauer

Yiwei Qi

Anthony Manning

John Schaeck

Yiming Yao

Kevin J McConnell

Pat Oliver-Shaffer

Zainab Sirajbhai Mamuwala

Ian David Fier

Ying Li

Miroslaw Lech

Kevin McConnell

Patrick Halvey

Described herein are methods for treating rheumatoid arthritis by determining whether a subject having rheumatoid arthritis will respond to an anti-TNF-alpha therapy based on the number of innate and adaptive immune cells in a sample from the subject prior to treatment.

Methods for predicting response to treatment

Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature, wherein, e.g., the structural signature is indicative of the methods used to make the heparin preparation.

Evaluating heparin preparations

Methods for analyzing mixtures of polysaccharides, for example heparin such as unfractionated heparin and enoxaparin are described. In some instances, the mixtures are analyzed using fast performance liquid chromatography (FPLC) and high liquid performance chromatography (HPLC), e.g., strong anion exchange HPLC.

Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping

Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided.

Low molecular weight heparin composition and uses thereof

Methods of evaluating heparin preparations, e.g., for suitability for use as a drug or for use in making a drug, by determining the absence, presence or amount of a structural signature that is indicative of the methods used to make the heparin preparation.

The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.

Chondroitinase ABC I and methods of degrading therewith

Methods for analyzing mixtures of polysaccharides, for example heparin or a LMWH, using reduce end labeling are described. In general, the mixture of polysaccharides includes polysaccharides having a desired structural moiety. In some instances, one or more polysaccharides in the mixture are chemically modified prior to analysis.

Methods of evaluating mixtures of polysaccharides

Methods for analyzing mixtures of polysaccharides, for example heparin such as enoxaparin are described. In some instances, the mixtures are analyzed using 1D NMR and/or 2D NMR.

Evaluating mixtures of low molecular weight heparins by NMR

Chondroitinase ABC I and methods of production

Chondroitinase ABC I and methods of analyzing therewith

Growing community of inventors

Ashland, MA, United States of America

Ishan Capila